Home > Keywords > Thématique > Science

Science

Articles

  • Vect-Horus focuses on Target engagement and intracellular delivery of LDLR conjugates to design new targeted drug therapies
    27 November 2019, by Elodie DORMES

    Varini et al. J Control Release 2019
    Targeted delivery to specific tissues and subcellular compartments is of paramount importance to optimize therapeutic or diagnostic interventions while minimizing side-effects. Using recently identified LDL receptor (LDLR) -targeting small synthetic peptide-vectors conjugated to model cargos of different nature and size, we investigated in LDLR-expressing cells the impact of vector-cargo molecular engineering and coupling valency, as well as the (…)

  • LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma
    30 September 2021, by Elodie DORMES

    Vect-Horus is proud to be part of the research in PDAC with its theranostic agents to first improve PDAC diagnosis, response monitoring or recurrence detection in operated patients and also treat them.
    Cedric malicet, Oncology Department Manager, is pleased to inform you of the recent publication of the article “ LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma “ in Communications Biology.

  • Vect-Horus strengthens its scientific advisory board with the appointment of Frédéric MATONTI
    16 May 2022, by Elodie DORMES

    Vect-Horus extends its Scientific Advisory Board with the expertise of Frédéric Matonti, a Leading Ophthalmology Specialist.

  • 3rd Annual RNAi-Based Therapeutics Summit from April 19th to 21th, 2022, in Boston
    12 April 2022, by Elodie DORMES

    Michel KHRESTCHATISKY, Scientific Counsel, will have a talk entitled “Development of Molecular Vectors for Targeted Delivery of RNAi” and Elodie DORMES, Sr BD Manager, will also be there and pleased to meet you in person during the summit.

  • Meet Vect-Horus at TIDES Europe in Vienna from November 16th to 18th, 2022.
    16 November 2022, by Elodie DORMES

    Guillaume JACQUOT will share a presentation on “Targeted delivery of Therapeutic Oligonucleotides to CNS by systemic administration” a good opportunity for Vect-Horus to present its last results.
    Emmanuelle BETTENDORF will be there as well to assist to conferences about Emerging #Oligonuleotide Therapeutics, #Delivery Strategies for Oligonucleotides, Peptides and mRNA and meet with all actors in the field.

  • Vect-Horus will present at Delivery of Macromolecules, June 8, 2022
    30 May 2022, by Elodie DORMES

    Guillaume JACQUOT, Head of Intracellular Trafficking & Translational Research, will give a talk on this occasion.

  • Two new patents protecting VECTrans® technology issued in several major countries
    28 January 2019, by Jonathan NOWAK

    Press release Communiqué de presse
    VECT-HORUS, a biotechnology company that designs and develops peptide vectors for addressing drugs or imaging agents to the brain and other organs, announces the strengthening of its patent portfolio with the granting of two patents in several major countries and particularly in the United States.
    These two patents protect peptide vectors that facilitate the targeting of drugs or imaging agents to organs, including the brain. Entitled “Peptide (…)

  • ECMED EU-GliaPhD international conference in MALTA
    28 January 2019, by Jonathan NOWAK

    Michel Khrestchatisky and Grigorios Kyriatzis (Early Stage Researcher, ESR), both members of the ITN Marie Curie project ECMED will participate in the ECMED EU-GliaPhD international conference organized in Malta, April 29 to May 2, 2018. Michel Khrestchatisky will give a talk on the ongoing projects of his group and biotechnology partner Vect-Horus, also member of the ECMED consortium, while Grigorios Kyriatzis presented results of his ongoing PhD project.

  • Festival of Biologics 2019 in BASEL
    31 October 2019, by Elodie DORMES

    Meet with Pascaline LECORCHE during the Festival of Biologics 2019, 15 – 17 October 2019 _ Basel Switzerland and discuss on « Design of peptide-based vectors for targeted delivery ».

  • Séminaire M&M’s – Muscle Monday Seminars of the Institute’s Myology Centre for Research on January 17, 2022
    17 January 2022, by Elodie DORMES

    Michel Khrestchatisky (CNRS Research Director, Director of the Institute for Neurophysiopathology) Co-Founder & Scientific Counsel of Vect-Horus presents "Development of molecular vectors for targeted delivery of RNAi via receptor-mediated transport" at the Muscle Monday Seminars organized by the Institute’s Myology Centre for Research.